CAMBRIDGE, Mass. (AP) -- Agios Pharmaceuticals said Thursday that it appointed Biogen Idec Chief Financial Officer Paul Clancy to its board of directors.
Agios said he joined the board on Tuesday and is filling a vacancy. Clancy has been Biogen Idec Inc.'s CFO since August 2007.
According to Agios' website, the company has nine directors including Clancy.
Agios Pharmaceuticals Inc. is developing biotech drugs intended to treat cancer and rare genetic diseases. The company went public in July with an IPO that priced at $18 a share, and the stock closed at $26.95 on Wednesday.
- Health Care Industry
- Board & Management Changes